Autologous peripheral blood-derived CD34+ cells

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Autologous peripheral blood-derived CD34+ cells
Accession Number
DB16367
Description

Autologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells.1 It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
  • CD34+ Cells
  • CLBS119
External IDs
  • Autologous peripheral blood-derived CD34+ cells

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

Autologous peripheral blood-derived CD34+ cells have potential tissue repair ability in part due to its anti-inflammatory function which were demonstrated in pre-clinical models, including one of lung inflammation.1 Due to the pre-programmed tissue repair effects mediated by anti-inflammatory and pro-angiogenic functions of these cells, this cell therapy is currently being investigated against COVID-19-induced lung damage in recovered adult patients that still are experiencing hypoxia and require supplemental oxygen.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Caladrius Biosciences: CLBS119 [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAdvanced Coronary Heart Disease / Chronic Myocardial Ischemia / Refractory Angina Pectoris1
3TerminatedSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas1
2Active Not RecruitingTreatmentMyelodysplastic Syndrome (MDS) With Refractory Anemia (RA) / Severe Aplastic Anemia (SAA)1
2CompletedTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
2CompletedTreatmentMyocardial Ischemia1
2CompletedTreatmentPlasma Cell Myeloma1
2RecruitingTreatmentAtherosclerosis Obliterans / Buerger's Disease / Critical Limb Ischemia (CLI) / Thromboangiitis Obliterans1
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2, 3CompletedTreatmentCritical Limb Ischemia (CLI)1
1Active Not RecruitingTreatmentCoronary Artery Atherosclerosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 18, 2020 09:55 / Updated on December 19, 2020 20:42

104